Thursday, September 19, 2019

Evidence underpinning approval of new cancer drugs raises questions

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, which indicates that treatment effects might have been exaggerated, concludes a new study.

from Latest Science News -- ScienceDaily https://ift.tt/31A1EwW
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists found the “holy grail” gene that could one day help humans regrow limbs

Scientists studying axolotls, zebrafish, and mice have uncovered a shared set of genes that may one day help humans regrow lost limbs. By id...